Finland· FI-REL-REL54730
Adakveo
A crizanlizumab product containing crizanlizumab, registered in Finland by Novartis Europharm Limited. The same ATC class is registered in 7 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Crizanlizumab is registered in 7 of 19 countries.
Countries holding a registration under ATC B06AX01 (crizanlizumab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Crizanlizumab · ATC B06AX01
7 / 19 countries
- Belgiumprice
- Finlandprice
- Franceprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Crizanlizumab
- Manufacturer
- Novartis Europharm Limited
- Country
- Finland (FI)
- ATC code
- B06AX01
- ATC class
- Crizanlizumab
- Defined daily dose
- 12.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Crizanlizumab in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAdakveo 10 mg/mlNovartis Europharm
- United StatesADAKVEONovartis Pharmaceuticals Corporation
- SpainADAKVEO 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONNovartis Europharm Limited
- FranceADAKVEO 10 mg/mL, solution à diluer pour perfusionNOVARTIS EUROPHARM (IRLANDE)
- United KingdomAdakveo 100mg/10ml concentrate for solution for infusion vialsNovartis Pharmaceuticals UK Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/82280ca2-0e38-45b5-b83b-2d04a83bcbfe GET /v1/drugs/82280ca2-0e38-45b5-b83b-2d04a83bcbfe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "12.5",
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": "mg",
"strength": "10 mg/ml",
"atc_label": "kritsanlitsumabi",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/20/1476/001",
"fimea_rel_id": "REL54730",
"authorised_at": "2020-10-28"
}See everything about crizanlizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.